

U.S. PRODUCERS' QUESTIONNAIRE
CALCIUM HYPOCHLORITE FROM CHINA

This questionnaire must be received by the Commission by no later than OCTOBER 2, 2014

See the Instruction Booklet for filing instructions.

The information called for in this questionnaire is for use by the United States International Trade Commission in connection with its countervailing duty and antidumping duty investigations concerning calcium hypochlorite ("calhypo") from China (Inv. Nos. 701-TA-510 and 731-TA-1245 (Final)). The information requested in the questionnaire is requested under the authority of the Tariff Act of 1930, title VII. This report is mandatory and failure to reply as directed can result in a subpoena or other order to compel the submission of records or information in your firm's possession (19 U.S.C. § 1333(a)).

Name of firm _____
Address _____
City _____ State _____ Zip Code _____
World Wide Web address _____
Has your firm produced calhypo (as defined in the instruction booklet) at any time since January 1, 2011?
<input type="checkbox"/> NO (Sign the certification below and promptly return only this page of the questionnaire to the Commission)
<input type="checkbox"/> YES (Read the instruction booklet carefully, complete all parts of the questionnaire, and return the entire questionnaire to the Commission so as to be received by the date indicated above)
Return questionnaire via the U.S. International Trade Commission Drop Box by clicking on the following link: https://dropbox.usitc.gov/oinv/. (use the following PIN: HYPO)

CERTIFICATION

I certify that the information herein supplied in response to this questionnaire is complete and correct to the best of my knowledge and belief and understand that the information submitted is subject to audit and verification by the Commission.

By means of this certification I also grant consent for the Commission, and its employees and contract personnel, to use the information provided in this questionnaire and throughout this proceeding in any other import-injury proceedings conducted by the Commission on the same or similar merchandise.

I acknowledge that information submitted in this questionnaire response and throughout this proceeding may be used by the Commission, its employees, and contract personnel who are acting in the capacity of Commission employees, for developing or maintaining the records of this proceeding or related proceedings for which this information is submitted, or in internal audits and proceedings relating to the programs and operations of the Commission pursuant to 5 U.S.C. Appendix 3. I understand that all contract personnel will sign non-disclosure agreements.

_____ <i>Name of Authorized Official</i>	_____ <i>Title of Authorized Official</i>	_____ <i>Date</i>
_____ <i>Signature</i>	_____ <i>Phone:</i>	_____ <i>Email address</i>
	_____ <i>Fax:</i>	

PART I.—GENERAL INFORMATION

The questions in this questionnaire have been reviewed with market participants to ensure that issues of concern are adequately addressed and that data requests are sufficient, meaningful, and as limited as possible. Public reporting burden for this questionnaire is estimated to average 50 hours per response, including the time for reviewing instructions, searching existing data sources, gathering the data needed, and completing and reviewing the questionnaire. Send comments regarding the accuracy of this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Office of Investigations, U.S. International Trade Commission, 500 E Street, SW, Washington, DC 20436.

I-1a. **OMB statistics.**--Please report below the actual number of hours required and the cost to your firm of preparing the reply to this questionnaire and completing the form.

Hours	Dollars

I-1b. **OMB feedback.**--We are interested in any comments you may have for improving this questionnaire in general or the clarity of specific questions. Please attach such comments to your firm's response or send them to the above address.

I-2. **Establishments covered.**-- Provide the city, state, zip code, and brief description of each establishment(s) covered by this questionnaire (see page 3 of the instruction booklet for reporting guidelines). If your firm is publicly traded, please specify the stock exchange and trading symbol in the footnote to the table.

Establishments Covered ¹	City, State	Zip (5 digit)	Description
1			
2			
3			
4			
5			
6			
¹ Additional discussion on establishments consolidated in this questionnaire: _____			

I-3. **Petition support.**--Does your firm support or oppose the petition?

Country	Support	Oppose	Take no position
China	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

PART I.--GENERAL INFORMATION--Continued

I-4. **Ownership.**--Is your firm owned, in whole or in part, by any other firm?

No Yes--List the following information.

Firm name	Address	Extent of ownership (percent)

I-5. **Related importers/exporters.**--Does your firm have any related firms, either domestic or foreign, that are engaged in importing calhypo from China into the United States or that are engaged in exporting calhypo from China to the United States?

No Yes--List the following information.

Firm name	Address	Affiliation

I-6. **Related producers.**--Does your firm have any related firms, either domestic or foreign, that are engaged in the production of calhypo?

No Yes--List the following information.

Firm name	Address	Affiliation

PART II.--TRADE AND RELATED INFORMATION

Further information on this part of the questionnaire can be obtained from **Fred Ruggles (202-205-3187, fred.ruggles@usitc.gov)**. **Supply all data requested on a calendar-year basis.**

II-1. **Contact information.**-- Please identify the responsible individual and the manner by which Commission staff may contact that individual regarding the confidential information submitted in part II.

Name	
Title	
Email	
Telephone	
Fax	

II-2. **Changes in operations.**--Please indicate whether your firm has experienced any of the following changes in relation to the production of calhypo since January 1, 2011.

- (check as many as appropriate)* *(please describe)*
- plant openings _____

 - plant closings..... _____

 - relocations _____

 - expansions..... _____

 - acquisitions..... _____

 - consolidations..... _____

 - prolonged shutdowns or
production curtailments..... _____

 - revised labor agreements..... _____

 - other (*e.g.*, technology) _____

PART II.--TRADE AND RELATED INFORMATION--Continued

II-3. **Same equipment, machinery, and workers for granules/powder or tablets & product shifting.**--Has your firm since 2011 produced, or does your firm anticipate producing in the future, other products on the same equipment and machinery used in the production of **granular/powder** or **tableted** calhypo and/or using the same production and related workers employed to produce **granular/powder** or **tableted** calhypo?

No Yes--Granular/powder (respond below) Yes--Tablets (respond below)

If you checked "yes" (meaning that your firm is able to switch production between granular/powder and other products or between tableted calhypo and other product using the same equipment and labor), please **identify the other products**, the approximate **time and cost** involved in switching, and the **minimum relative price change required** for your firm to switch production to or from granular/powder or tableted calhypo.

II-4. **Production constraints and product shifting.**--Please describe the constraint(s) that set the limit(s) on your firm's production capacity and its ability to shift production capacity between products.

II-5. **Type of operation.**--Since January 1, 2011, which of the following activity is your firm involved in the production of calhypo (check all that apply)?

Bulk granular/powder Tablets

II-6. **Tolling.**--Since January 1, 2011, has your firm been involved in a toll agreement (see definition in the instruction booklet) regarding the production of calhypo?

No Yes--Name firm(s): _____.

If yes, check all that apply:

Your firm is a tollee (*i.e.*, contracts out for the tableting production of calhypo).

Your firm is a toller (*i.e.*, produces tableted calhypo under contract for other firm(s)).

IF YOUR FIRM IMPORTED GRANULAR/POWDER CALHYPO THAT IS TABLETED UNDER A TOLLING ARRANGEMENT WITH A THIRD PARTY IN THE UNITED STATES, REPORT YOUR SHIPMENTS AND SALES OF THE TOLL-PRODUCED TABLETS IN YOUR U.S. IMPORTERS' QUESTIONNAIRE. THE TOLL PRODUCER SHOULD COMPLETE THOSE PARTS OF THIS U.S. PRODUCERS' QUESTIONNAIRE ASSOCIATED WITH ITS TOLL PRODUCTION.

PART II.--TRADE AND RELATED INFORMATION--Continued

II-7. **Foreign trade zone**--Does your firm produce calhypo in a foreign trade zone (FTZ)?

No Yes--Identify FTZ(s): _____.

II-8. **Importer**--Since January 1, 2011, has your firm imported calhypo?

No Yes--**COMPLETE AND RETURN A U.S. IMPORTERS' QUESTIONNAIRE**

PART II.--TRADE AND RELATED INFORMATION--Continued

II-9. **GRANULAR/POWDER CALHYPO.**--Report your firm's production capacity, production, shipments, inventories, and employment related to the production of **all granular/powder calhypos** in its U.S. establishment(s) during the specified periods. (See definitions in the instruction booklet.)

Quantity (in 1,000 pounds) and value (in \$1,000)					
Item	Calendar years			January-June	
	2011	2012	2013	2013	2014
Average production capacity ¹ (quantity)					
Beginning-of-period inventories (quantity)					
Production (quantity)					
U.S. shipments:					
Commercial shipments:					
Quantity of commercial shipments					
Value of commercial shipments					
Internal consumption:					
Quantity of internal consumption					
Value ² of internal consumption					
Transfers to related firms:					
Quantity of transfers					
Value ² of transfers					
Shipped for toll conversion: ³					
Quantity of merchandise shipped for tolling					
Value of merchandise shipped for tolling					
Value tolling fee contracted/paid					
Export shipments: ⁴					
Quantity of export shipments					
Value of export shipments					
End-of-period inventories ⁵ (quantity)					
Employment data:					
Average number of PRWs (number)					
Hours worked by PRWs (1,000 hours)					
Wages paid to PRWs (value)					
<p>¹ The production capacity (see definitions in instruction booklet) reported is based on operating _____ hours per week, _____ weeks per year. Please describe the methodology used to calculate production capacity, and explain any changes in reported capacity (use additional pages as necessary).</p> <hr/> <p>² Internal consumption and transfers to related firms must be valued at fair market value. In the event that your firm uses a different basis for valuing these transactions, please specify that basis (e.g., cost, cost plus, etc.) and provide value data using that basis for each of the periods noted above:</p> <hr/> <p>³ Merchandise shipped for toll conversion is understood to mean any powder/granular calhypos your firm ships to any third party (related or not) for conversion into tablets under a toll arrangement.</p> <p>⁴ Identify your firm's principal export markets: _____.</p> <p>⁵ Reconciliation of data.--Please note that the quantities reported above should reconcile as follows: beginning-of-period inventories, plus production, less total shipments, equals end-of-period inventories. Do the data reported reconcile?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No--Please explain: _____.</p>					

PART II.--TRADE AND RELATED INFORMATION--Continued

II-10. **CHANNELS OF DISTRIBUTION FOR GRANULAR/POWDER CALHYPO.**--Report your firm's total U.S. commercial shipments of powder/granular form of calhypo, by channel of distribution from its U.S. establishment(s) during the specified periods.

Quantity (in 1,000 pounds)					
Item	Calendar years			January-June	
	2011	2012	2013	2013	2014
Retail market					
Repackers/private label marketers/tableters					
Distributors and dealers for private and residential or commercial swimming pool channels					
Retailers/big-box stores					
Service professionals (maintenance and services to consumers and institutions)					
Consumer and commercial swimming pools, spas, etc.					
Institutional and industrial applications					
Manufacturers of bulk chemicals					
Municipal water treatment					
Total U.S. commercial shipments	0	0	0	0	0

Reconciliation of Channels of Distribution.--Please ensure that the quantities reported for channels of distribution (i.e., above) in each time period equal the quantities reported for commercial U.S. shipments from question II-9 in each time period. The calculated fields test this reconciliation. If the calculated fields below return values other than zero (i.e., "0"), the data in question II-9 or II-10 need to be revised prior to submission to the Commission.

Reconciliation item	Calendar years			January-June	
	2011	2012	2013	2013	2014
Should equal to zero (revise data II-9 or II-10 if not zero)	0	0	0	0	0

PART II.--TRADE AND RELATED INFORMATION--Continued

II-11. **TABLETED CALHYPO**--Report your firm's production capacity, production, shipments, and inventories related to the production of **all tableted calhypos** in its U.S. establishment(s).

Quantity (in 1,000 pounds) and value (in \$1,000)					
Item	Calendar years			January-June	
	2011	2012	2013	2013	2014
Average production capacity¹ (quantity) (A)					
Beginning-of-period inventories (quantity) (B)					
Source of tablets:					
Production of tablets:					
From internally produced granular/powder calhypos (C)					
From U.S.-produced granular/powder calhypos (D)					
From imported granular/powder calhypos (E)					
From granular/powder calhypos received pursuant to a toll arrangement (F) ²					
Subtotal: production of tablets	0	0	0	0	0
Finished product received from toll operations: (quantity) (G)³					
U.S. shipments of tableted calhypos:					
Commercial shipments:					
Quantity of commercial shipments (H)					
Value of commercial shipments (I)					
Internal consumption:					
Quantity of internal consumption (J)					
Value ⁴ of internal consumption (K)					
Transfers to related firms:					
Quantity of transfers (L)					
Value ⁴ of transfers (M)					
Toll production returned:⁵					
Quantity shipped back to tollee (N)					
Value fee(s) received for returned tablets (O)					
Export shipments of tableted:⁶					
Quantity of export shipments (P)					
Value of export shipments (Q)					
End-of-period inventories (quantity) (R)					
Employment data:					
Average number of PRWs (number)					
Hours worked by PRWs (1,000 hours)					
Wages paid to PRWs (value)					

See footnotes on next page.

PART II.--TRADE AND RELATED INFORMATION--Continued

II-11. TABLETED CALHYPO.--Continued

¹ The production capacity (see definitions in instruction booklet) reported is based on operating _____ hours per week, _____ weeks per year. Please describe the methodology used to calculate production capacity, and explain any changes in reported capacity (use additional pages as necessary).

² Report the data here for tablets your firm produced under a toll arrangement for which you are receiving a fee your production services. To the degree to which the product is shipped back to the tollee within the period of production those data should also be reported in line N of this data table.

³ Report the data here for tablets your firm received under a toll arrangement for which you paid a third party to convert into tablets. Any sales or shipments of the tablets into the market should be reported under commercial shipments, internal consumption, or transfers to related firms (e.g., not under "toll production returned").

⁴ Internal consumption and transfers to related firms must be valued at fair market value. In the event that your firm uses a different basis for valuing these transactions, please specify that basis (e.g., cost, cost plus, etc.) and provide value data using that basis for each of the periods noted above:

⁵ Toll production returned only applies to tollers who have converted powder/granular form calhypto to tablets for another firm and have shipped those tablets back to the tollee who will actually end up selling them into the market.

⁶ Identify your firm's principal export markets: _____.

II-12. CHANNELS OF DISTRIBUTION FOR TABLETED CALHYPO.--Report your firm's total U.S. commercial shipments of tableted calhypto, by channel of distribution from its U.S. establishment(s) during the specified periods.

Item	Quantity (in 1,000 pounds)				
	Calendar years			January-June	
	2011	2012	2013	2013	2014
Retail market					
Repackers/private label marketers/tableters					
Distributors and dealers for private and residential or commercial swimming pool channels					
Retailers/big-box stores					
Service professionals (maintenance and services to consumers and institutions)					
Consumer and commercial swimming pools, spas, etc.					
Institutional and industrial applications					
Manufacturers of bulk chemicals					
Municipal water treatment					
Total U.S. commercial shipments	0	0	0	0	0

Reconciliation of Channels of Distribution.--Please ensure that the quantities reported for channels of distribution (i.e., above) in each time period equal the quantities reported for commercial U.S. shipments from question II-11 in each time period. The calculated fields test this reconciliation. If the calculated fields below return values other than zero (i.e., "0"), the data in question II-11 or II-12 need to be revised prior to submission to the Commission.

Reconciliation item	Calendar years			January-June	
	2011	2012	2013	2013	2014
Should equal to zero (revise data in II-11 or II-12 if not zero)	0	0	0	0	0

PART II.--TRADE AND RELATED INFORMATION--Continued

II-13. **Related firms.**--If your firm reported transfers to related firms in question II-9, please indicate the nature of the relationship between your firm and the related firms (*e.g.*, joint venture, wholly owned subsidiary), whether the transfers were priced at market value or by a non-market formula, whether your firm retained marketing rights to all transfers, and whether the related firms also processed inputs from sources other than your firm.

II-14. **Purchases.**--Other than direct imports, has your firm otherwise purchased calhyo since January 1, 2011? (See definitions in the instruction booklet.)

No Yes--Report such purchases below for the specified periods.¹

(Quantity in 1,000 pounds, value in \$1,000)					
Item	Calendar years			January-June	
	2011	2012	2013	2013	2014
PURCHASES FROM U.S. IMPORTERS² OF CALHYO FROM—					
China:					
Quantity					
Value					
All other countries:					
Quantity					
Value					
PURCHASES FROM DOMESTIC PRODUCERS:²					
Quantity					
Value					
PURCHASES FROM OTHER SOURCES:²					
Quantity					
Value					
¹ Please indicate your firm's reasons for purchasing this product. If your firm's reasons differ by source, please elaborate.					
² Please list the name of the firm(s) from which your firm purchased this product. If your firm's suppliers differ by source, please identify the source for each listed supplier.					

PART II.--TRADE AND RELATED INFORMATION--Continued

II-15. **Differences associated with producing granular/powder versus tablets.**--Please provide a discussion of any differences involved in your firms' U.S. production-related activities for granular/powder versus tablet production, including the technical expertise needed for granular/powder versus tablet production; the quantity and type of parts sourced in the United States for granular/powder versus tablet production; and any other costs and activities involved in granular/powder versus tablet production. Use additional pages as necessary.

II-16. **Other explanations.**--If your firm would like to further explain a response to a question in Part II that did not provide a narrative response box, please note the question number and the explanation in the space provided below. Please also use this space to highlight any issues your firm had in providing the data in this section, including but not limited to technical issues with the MS Word questionnaire.

PART III.--FINANCIAL INFORMATION

Note: If you are answering this questionnaire because you are a toller that converts powder/granular form calcium hypochlorite into tablet form for a third party under a tolling agreement (and do not produce powder/granular form calcium hypochlorite) and you also repackage calcium hypochlorite without converting between forms, limit your response to this section of the questionnaire to information related to the tableting operation. Do not include information related to the repackaging operation. In Question III-4, please explain how financial information was allocated between the two operations.

Address questions on this part of the questionnaire to **David Boyland (202-708-4725, David.Boyland@usitc.gov)**.

III-1. **Contact information**--Please identify the responsible individual and the manner by which Commission staff may contact that individual regarding the confidential information submitted in part III.

Name	
Title	
Email	
Telephone	
Fax	

III-2. **Accounting system**--Briefly describe your firm's financial accounting system.

- A. When does your firm's fiscal year end (month and day)? _____
If your firm's fiscal year changed during the data-collection period, explain below:

- B.1. Describe the lowest level of operations (e.g., plant, division, company-wide) for which financial statements are prepared that include calhyo:

- 2. Does your firm prepare profit/loss statements for the calhyo:
 Yes No
- 3. How often did your firm (or parent company) prepare financial statements (including annual reports, 10Ks)? Please check relevant items below.
 Audited, unaudited, annual reports, 10Ks, 10 Qs,
 Monthly, quarterly, semi-annually, annually
- 4. Accounting basis: GAAP, cash, tax, or other comprehensive basis of accounting (specify) _____

Note: The Commission may request that your company submit copies of its financial statements, including internal profit-and-loss statements for the division or product group that includes calhyo, as well as those statements and worksheets used to compile data for your firm's questionnaire response.

PART III.--FINANCIAL INFORMATION--Continued

III-3. **Cost accounting system.**--Briefly describe your firm's cost accounting system (*e.g.*, standard cost, job order cost, *etc.*).

III-4. **Allocation basis.**--Briefly describe your firm's allocation basis, if any, for COGS, SG&A, and interest expense and other income and expenses. (See note at the beginning of this section regarding distinction between tableting and repackaging operations).

III-5. **Other products.**—Please list any other products your firm produced in the facilities in which your firm produced calhypo, and provide the share of net sales accounted for by these other products in your firm's most recent fiscal year:

Products	Share of sales
calhypo	%
	%
	%
	%
	%

III-6. Does your firm purchase **inputs** (raw materials, labor, energy, or any other services) used in the production of calhypo from any related parties?

- Yes--Continue to question III-7 below. No--Continue to question III-9a below.

PART III.--FINANCIAL INFORMATION--Continued

III-7. **Inputs from related parties.**--In the space provided below, identify the inputs used in the production of calhypo that your firm purchases from related parties. For "Share of total COGS" please report this information by relevant input on the basis of your most recently completed fiscal year. For "Input valuation" please describe the basis, as recorded in the company's own accounting system, of the purchase cost from the related party; e.g., the related party's actual cost, cost plus, negotiated transfer price to approximate fair market value.

<u>Input</u>	<u>Related party</u>	<u>Share of total COGS</u>
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____

Input valuation

III-8. **Inputs from related parties at cost.**-- All intercompany profit or loss on inputs purchased from related parties, as well as intra-division profit or loss, should be eliminated from the costs reported to the Commission in question III-9a; i.e., costs reported in question III-9a should only reflect the related party's cost and not include an associated profit or loss component. Reasonable methods for determining and eliminating the associated profit on inputs purchased from related parties are acceptable.

Has your firm complied with the Commission's instructions regarding costs associated with inputs purchased from related parties?

Yes--Please briefly describe how you eliminated intercompany/intra-division profit or (loss) on inputs purchased/received from related firms/or intra-division units within the same company to arrive at the actual costs incurred by the related firms/intra-division units.

No-- If an inter-company/intra-division profit or (loss) adjustment was applicable, please explain why this adjustment was not made.

PART III.--FINANCIAL INFORMATION--Continued

III-9a. **Operations on calhypo.**--Report the revenue and related cost information requested below on the calhypo operations of your firm's U.S. establishment(s).¹ Do **not report resales** of products. Note that **internal consumption and transfers to related firms must be valued at fair market value and purchases from related firms must be at cost.**² Provide data for your firm's three most recently completed fiscal years, and for the specified interim periods.

Quantity (in 1,000 pounds) and value (in \$1,000)					
Item	Fiscal years ended--			January-June	
	2011	2012	2013	2013	2014
Net sales quantities: ³					
Commercial sales ("CS")					
Internal consumption ("IC")					
Transfers to related firms ("Transfers")					
Total net sales quantities	0	0	0	0	0
Net sales values: ³					
Commercial sales					
Internal consumption					
Transfers to related firms					
Total net sales values	0	0	0	0	0
Cost of goods sold (COGS): ⁴					
Raw materials					
Direct labor					
Other factory costs					
Total COGS	0	0	0	0	0
Gross profit or (loss)	0	0	0	0	0
Selling, general, and administrative (SG&A) expenses:					
Selling expenses					
General and administrative expenses					
Total SG&A expenses	0	0	0	0	0
Operating income (loss)	0	0	0	0	0
Other expenses and income:					
Interest expense					
All other expense items					
All other income items					
Net income or (loss) before income taxes	0	0	0	0	0
Depreciation/amortization included above					

¹ Include only sales (whether domestic or export) and costs related to your U.S. manufacturing operations.
² Please eliminate any profits or (losses) on inputs from related firms pursuant to question III-8.
³ Less discounts, returns, allowances, and prepaid freight. The quantities and values should approximate the corresponding shipment quantities and values reported in Part II of this questionnaire.
⁴ COGS should include costs associated with CS, IC, and Transfers, as well as export shipments as reported in the relevant trade section in part II.

Note -- The table above contains calculations that will appear when you have entered data in the MS Word form fields.

PART III.--FINANCIAL INFORMATION--Continued

III-9b. **Financial data reconciliation.**--The calculable line items from question III-9a. (*i.e.*, total net sales quantities and values, total COGS, gross profit (or loss), total SG&A, and net income (or loss)) have been calculated from the data submitted in the other line items. Do the calculated fields return the correct data according to your firm's financial records ignoring non-material differences that may arise due to rounding?

Yes No.--If the calculated fields do not show the correct data, please double check the feeder data for data entry errors and revise.

Also, check signs accorded to the post operating income line items; the two expense line items should report positive numbers (*i.e.*, expenses are positive and incomes or reversals are negative--instances of the latter should be rare in those lines) while the income line item also in most instances should have its value be a positive number (*i.e.*, income is positive, expenses or reversals are negative).

If after reviewing and potentially revising the feeder data your firm has provided, the differences between your records and the calculated fields persist please identify and discuss the differences in the space below.

III-10. **Nonrecurring items (charges and gains) included in the subject product financial results.**-- For each annual and interim period for which financial results are reported in question III-9a, please specify all material (significant) nonrecurring items (charges and gains) in the schedule below, the specific table III-9a line item where the nonrecurring items are included, a brief description of the relevant nonrecurring items, and the associated values (*in \$1,000*), as reflected in table III-9a; *i.e.*, if an aggregate nonrecurring item has been allocated to table III-9a, only the allocated value amount included in table III-9a should be reported in the schedule below. Note: The Commission's objective here is to gather information only on material (significant) nonrecurring items which impacted the reported financial results of the subject product in table III-9a.

	Fiscal years ended--			January-June	
	2011	2012	2013	2013	2014
Nonrecurring item: In this column please provide a brief description of each nonrecurring item and indicate the specific line item in table III-9a where the nonrecurring item is classified.	Nonrecurring item: In these columns please report the amount of the relevant nonrecurring item reported in table III-9a. Value (\$1,000)				
1. , classified					
2. , classified					
3. , classified					
4. , classified					
5. , classified					
6. , classified					
7. , classified					

PART III.--FINANCIAL INFORMATION--Continued

III-11. Does your firm repackage as well as tablet calhypo products?

Yes No

If yes, please explain the basis for identifying and attributing the information reported in III-12 (property, plant and equipment) and III-13a (capital expenditures and R&D expenses) to either the repackaging operation or the tableting operation:

III-12. **Property, plant and equipment.**--Report the property, plant, and equipment (PP&E) associated with the designated calhypo operations identified below. If your firm does not maintain in the normal course of business some or all of the specific information necessary to calculate PP&E relevant to the designated calhypo operations, please estimate this information based upon a method (such as production, sales, or costs) that is consistent with your firm's cost allocations in table III-9a and/or III-13a. Provide data for your firm's three most recently completed fiscal years, and for the specified interim periods.

Note: Total property, plant, and equipment should reflect net assets after any accumulated depreciation and allowances deducted. Total property, plant, and equipment should be allocated to the subject products if the underlying assets are also related to other products. In the space below, please provide a brief explanation if there were any substantial changes in total property, plant, and equipment value during the period; e.g., due to asset write-offs, revaluation, and major purchases.

Value (in \$1,000)					
Item	Fiscal years ended--			January-June	
	2011	2012	2013	2013	2014
Total PP&E – granular/powder operations					
Total PP&E – tableting operations					

III-13a. **Capital expenditures and research and development expenses.**--Report your firm's capital expenditures and general research and development (R&D) expenses for designated calhypo operations. Provide data for your firm's three most recently completed fiscal years, and for the specified interim periods.

Value (in \$1,000)					
Item	Fiscal years ended--			January-June	
	2011	2012	2013	2013	2014
Capital expenditures – granular/powder operations					
Capital expenditures – tableting operations					
R&D expenses – granular/powder operations					
R&D expenses – tableting operations					

PART III.--FINANCIAL INFORMATION--Continued

III-13b. **Capital expenditures.**--Please indicate the nature, focus, and significance of your firm's capital expenditures on the subject product.

III-14. **Data consistency and reconciliation.**--Please indicate whether your firm's financial data for questions III-9a, 12, and 13a are based on a calendar year or on your firm's fiscal year:

Calendar year	Fiscal year	Specify fiscal year
<input type="checkbox"/>	<input type="checkbox"/>	

Please note the quantities and values reported in question III-9a should reconcile with the relevant trade data (including export shipments) reported in part II of this questionnaire; i.e., as long as they are reported on the same calendar year basis.

Do these data in question III-9a reconcile with the relevant trade data reported in part II of this questionnaire?

Yes	No	If no, please explain.
<input type="checkbox"/>	<input type="checkbox"/>	

III-15a. **Effects of imports.**--Since January 1, 2011, has your firm experienced any actual negative effects on its return on investment or its growth, investment, ability to raise capital, existing development and production efforts (including efforts to develop a derivative or more advanced version of the product), or the scale of capital investments as a result of imports of calhypo from China?

No Yes--My firm has experienced actual negative effects as follows:

<input type="checkbox"/>	Cancellation, postponement, or rejection of expansion projects
<input type="checkbox"/>	Denial or rejection of investment proposal
<input type="checkbox"/>	Reduction in the size of capital investments
<input type="checkbox"/>	Rejection of bank loans
<input type="checkbox"/>	Lowering of credit rating
<input type="checkbox"/>	Problem related to the issue of stocks or bonds
<input type="checkbox"/>	Other (specify):

PART III.--FINANCIAL INFORMATION--Continued

III-15b. **Anticipated effects of imports.**--Does your firm anticipate any negative effects due to imports of calhypo from China?

No	Yes	If yes, my firm anticipates negative effects as follows:
<input type="checkbox"/>	<input type="checkbox"/>	

III-16. **Other explanations:**--If your firm would like to further explain a response to a question in Part III that did not provide a narrative box, please note the question number and the explanation in the space provided below. Please also use this space to highlight any issues your firm had in providing the data in this section, including but not limited to technical issues with the MS Word questionnaire.

PART IV.--PRICING AND RELATED INFORMATION

Further information on this part of the questionnaire can be obtained from James Fetzer (202-708-5403, James.Fetzer@usitc.gov)

IV-1. **Contact information.**--Please identify the individual that Commission staff may contact regarding the confidential information submitted in part IV.

Name	
Title	
Email	
Telephone	
Fax	

PRICE DATA

IV-2. This question requests quarterly quantity and value data, f.o.b. your firm's U.S. point of shipment, for your firm's commercial shipments to unrelated U.S. customers since January 1, 2011 of the following products produced by your firm.

Note that some or all of the products that you produce may not match these specifications. If that is the case, do not report data for these products unless the product is competitive with one of these products. However, please respond to the other questions in Part IV with respect to all your sales or use of calhypo.

Product 1. -- Calcium Hypochlorite, 65%-73% available chlorine, granular, 100 lbs., however packaged, sold into the repacker/private label/tableter channel.

Product 2.-- Calcium Hypochlorite, 65%-73% available chlorine, granular, 100 lbs., however packaged, sold directly to distributors or dealers that serve the private residential or commercial swimming pool channels.

Product 3. -- Calcium Hypochlorite, 65%-73% available chlorine, granular, 100 lbs., however packaged, sold to retailers/big box stores.

Product 4. -- Calcium Hypochlorite, 65%-73% available chlorine, granular, 25 lbs., however packaged, sold into the repacker/private label/tableter channel.

Product 5.-- Calcium Hypochlorite, 65%-73% available chlorine, granular, 25 lbs., however packaged, sold directly to distributors or dealers that serve the private residential or commercial swimming pool channels.

Product 6. -- Calcium Hypochlorite, 65%-73% available chlorine, granular, 25 lbs., however packaged, sold to retailers/big box stores.

Please note that total dollar values should be f.o.b., U.S. point of shipment and should not include U.S.-inland transportation costs. Total dollar values should reflect the *final net* amount paid to your firm (i.e., should be net of all deductions for discounts or rebates). See instruction booklet.

During January 2011-June 2014, did your firm produce and sell to unrelated U.S. customers any of the above listed products (or any products that were competitive with these products)?

<input type="checkbox"/>	Yes. --Please complete the following pricing data table as appropriate.
<input type="checkbox"/>	No. --Skip to question IV-3.

PART IV.--PRICING AND RELATED INFORMATION--Continued

IV-2. **Pricing data.**--Report below the quarterly price data¹ for pricing products² produced and sold by your firm.

Report data in actual pounds and actual dollars (not 1,000s).

(Quantity in pounds, value in dollars)						
Period of shipment	Product 1		Product 2		Product 3	
	Quantity	Value	Quantity	Value	Quantity	Value
2011:						
January-March						
April-June						
July-September						
October-December						
2012:						
January-March						
April-June						
July-September						
October-December						
2013:						
January-March						
April-June						
July-September						
October-December						
2014:						
January-March						
April-June						

¹ Net values (*i.e.*, gross sales values less all discounts, allowances, rebates, prepaid freight, and the value of returned goods), f.o.b. your firm's U.S. point of shipment.

² Pricing product definitions are provided on the first page of Part IV.

Note.--If your firm's product does not exactly meet the product specifications but is competitive with the specified product, provide a description of your firm's product. Also, please explain any anomalies in your firm's reported pricing data.

Product 1:

Product 2:

Product 3:

PART IV.--PRICING AND RELATED INFORMATION--Continued

IV-2. **Pricing data (continued).**--Report below the quarterly price data¹ for pricing products² produced and sold by your firm.

Report data in actual pounds and actual dollars (not 1,000s).

(Quantity in pounds, value in dollars)						
Period of shipment	Product 4		Product 5		Product 6	
	Quantity	Value	Quantity	Value	Quantity	Value
2011:						
January-March						
April-June						
July-September						
October-December						
2012:						
January-March						
April-June						
July-September						
October-December						
2013:						
January-March						
April-June						
July-September						
October-December						
2014:						
January-March						
April-June						

¹ Net values (*i.e.*, gross sales values less all discounts, allowances, rebates, prepaid freight, and the value of returned goods), f.o.b. your firm's U.S. point of shipment.

² Pricing product definitions are provided on the first page of Part IV.

Note.--If your firm's product does not exactly meet the product specifications but is competitive with the specified product, provide a description of your firm's product. Also, please explain any anomalies in your firm's reported pricing data.

Product 4:

Product 5:

Product 6:

PART IV.--PRICING AND RELATED INFORMATION--Continued

IV-3. **Price setting.**-- How does your firm determine the prices that it charges for sales of calhypo (*check all that apply*)? If your firm issues price lists, please submit sample pages of a recent list.

Transaction by transaction	Contracts	Set price lists	Other	If other, describe
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

IV-4. **Discount policy.**-- Please indicate and describe your firm's discount policies (*check all that apply*).

Quantity discounts	Annual total volume discounts	No discount policy	Other	Describe
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

IV-5. **Customer rewards programs.**--

(a) Does your firm offer customer rewards programs for products including calhypo?

<input type="checkbox"/>	No -- skip to question IV-6.
<input type="checkbox"/>	Yes -- please respond to part (b)

(b) Identify the share of your firm's 2013 sales of calhypo that were affected by a customer rewards program and estimate the total cost of the rewards program.

Share of your firm's 2013 sales of calhypo that were part of a customer rewards program	%
Estimate the total cost of customer rewards programs that could have affected sales of calhypo	

IV-6. **Pricing terms for calhypo.**--

(a) What are your firm's typical sales terms for its U.S.-produced calhypo?

Net 30 days	Net 60 days	2/10 net 30 days	Other	Other (specify)
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

(b) On what basis are your firm's prices of domestic calhypo usually quoted (*check one*)?

Delivered	F.o.b.	If f.o.b., specify point
<input type="checkbox"/>	<input type="checkbox"/>	

PART IV.--PRICING AND RELATED INFORMATION--Continued

IV-7. **Contract versus spot.**--Approximately what share of your firm's sales of its U.S.-produced calhypo in 2013 was on a (1) long-term contract basis, (2) short-term contract basis, and (3) spot sales basis?

Type of sale	Share of 2013 sales
Long-term contracts (multiple deliveries for more than 12 months)	%
Short-term contracts (multiple deliveries up to and including 12 months)	%
Spot sales (for a single delivery)	%
Total (should sum to 100%)	0.0 %

IV-8. **Contract provisions.**— Please fill out the table with respect to provisions of your firm's typical sales contracts for calhypo (or check "not applicable" if your firm does not sell on a long-term and/or short-term contract basis).

Typical sales contract provisions	Item	Short-term contracts (multiple deliveries up to and including 12 months)	Long-term contracts (multiple deliveries for more than 12 months)
Average contract duration	<i>Number of days</i>		
Price renegotiation (during the contract period)	<i>Yes</i>	<input type="checkbox"/>	<input type="checkbox"/>
	<i>No</i>	<input type="checkbox"/>	<input type="checkbox"/>
Fixed quantity and/or price	<i>Quantity</i>	<input type="checkbox"/>	<input type="checkbox"/>
	<i>Price</i>	<input type="checkbox"/>	<input type="checkbox"/>
	<i>Both</i>	<input type="checkbox"/>	<input type="checkbox"/>
Meet or release provision	<i>Yes</i>	<input type="checkbox"/>	<input type="checkbox"/>
	<i>No</i>	<input type="checkbox"/>	<input type="checkbox"/>
Not applicable		<input type="checkbox"/>	<input type="checkbox"/>

IV-9. **Lead times.**--What is your firm's share of sales both from inventory and produced to order and what is the typical lead time between a customer's order and the date of delivery for your firm's sales of its U.S.-produced calhypo?

Source	Share of 2013 sales	Lead time (days)
From inventory	%	
Produced to order	%	
Total (should sum to 100%)	0.0 %	

PART IV.--PRICING AND RELATED INFORMATION--Continued

IV-10. Shipping information.--

- (a) What is the approximate percentage of the total delivered cost of calhypo that is accounted for by U.S. inland transportation costs? _____ %
- (b) Who generally arranges the transportation to your firm's customers' locations?
 Your firm Purchaser (*check one*)
- (c) Indicate the approximate percentage of your firm's sales of calhypo that are delivered the following distances from its production facility.

Distance from production facility	Share
Within 100 miles	%
101 to 1,000 miles	%
Over 1,000 miles	%
Total (should sum to 100%)	0.0 %

- IV-11. **Geographical shipments.**-- In which U.S. geographic market area(s) has your firm sold its U.S.-produced calhypo since January 1, 2011 (check all that apply)?

Geographic area	√ if applicable
Northeast. --CT, ME, MA, NH, NJ, NY, PA, RI, and VT.	<input type="checkbox"/>
Midwest. --IL, IN, IA, KS, MI, MN, MO, NE, ND, OH, SD, and WI.	<input type="checkbox"/>
Southeast. --AL, DE, DC, FL, GA, KY, MD, MS, NC, SC, TN, VA, and WV.	<input type="checkbox"/>
Central Southwest. --AR, LA, OK, and TX.	<input type="checkbox"/>
Mountains. --AZ, CO, ID, MT, NV, NM, UT, and WY.	<input type="checkbox"/>
Pacific Coast. --CA, OR, and WA.	<input type="checkbox"/>
Other. --All other markets in the United States not previously listed, including AK, HI, PR, and VI, among others.	<input type="checkbox"/>

- IV-12. **End uses.**--List the end uses of the calhypo that your firm manufactures. For each end-use product, what percentage of the total cost is accounted for by calhypo and other inputs?

End use product	Share of total cost of end use product accounted for by		Total
	Calhypo	Other inputs	
	%	%	0.0 %
	%	%	0.0 %
	%	%	0.0 %

PART IV.--PRICING AND RELATED INFORMATION--Continued

IV-13. **Substitutes.**-- Can other products be substituted for calhypo?

No Yes--Please fill out the table.

	Substitute	End use in which this substitute is used	Have changes in the prices of this substitute affected the price for calhypo?		
			No	Yes	Explanation
1.			<input type="checkbox"/>	<input type="checkbox"/>	
2.			<input type="checkbox"/>	<input type="checkbox"/>	
3.			<input type="checkbox"/>	<input type="checkbox"/>	

IV-14. **Chlorine content.**--

(a) Can calhypo products that differ only in their available chlorine levels serve as commercial substitutes with little or no reprocessing by the seller?

No	Yes	Explain
<input type="checkbox"/>	<input type="checkbox"/>	

(b) Report the share of your firm's U.S. commercial shipments of calhypo by available chlorine content.

Chlorine content	Share of 2013 U.S. commercial shipments
47 – 56 percent	%
65 – 68 percent	%
70 percent and above	%
Other:	%
Total (should sum to 100%)	0.0 %

PART IV.--PRICING AND RELATED INFORMATION--Continued

IV-15. **Demand trends.**-- Indicate how demand within the United States and outside of the United States (if known) for calhypo has changed since January 1, 2011. Explain any trends and describe the principal factors that have affected these changes in demand.

Market	Overall increase	No change	Overall decrease	Fluctuate with no clear trend	Explanation and factors
Within the United States	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Outside the United States	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

IV-16. **Product changes.**--Have there been any significant changes in the product range, product mix, or marketing of calhypo since January 1, 2011?

No	Yes	If yes, please describe and quantify if possible.
<input type="checkbox"/>	<input type="checkbox"/>	

IV-17. **Business cycles.**--

(a) Is the calhypo market subject to business cycles (other than general economy-wide conditions) and/or other conditions of competition distinctive to calhypo?

Check all that apply.	Please describe.
<input type="checkbox"/> No	Skip to question IV-18.
<input type="checkbox"/> Yes-Business cycles (e.g. seasonal business)	
<input type="checkbox"/> Yes-Other distinctive conditions of competition	

(b) If yes, have there been any changes in the business cycles or conditions of competition for calhypo since January 1, 2011?

No	Yes	If yes, please describe.
<input type="checkbox"/>	<input type="checkbox"/>	

PART IV.--PRICING AND RELATED INFORMATION--Continued

IV-18. **Supply constraints.**--Has your firm refused, declined, or been unable to supply calhypo since January 1, 2011 (examples include placing customers on allocation or "controlled order entry," declining to accept new customers or renew existing customers, delivering less than the quantity promised, been unable to meet timely shipment commitments, etc.)?

No	Yes	If yes, please describe.
<input type="checkbox"/>	<input type="checkbox"/>	

IV-19. **Raw materials.**--How have calhypo raw materials prices changed since January 1, 2011?

Overall increase	No change	Overall decrease	Fluctuate with no clear trend	Explain, noting how raw material price changes have affected your firm's selling prices for calhypo.
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

IV-20. **Interchangeability.**--Is calhypo produced in the United States and in other countries interchangeable (*i.e.*, can they physically be used in the same applications)?

Please indicate A, F, S, N, or 0 in the table below:

A = the products from a specified country-pair are *always* interchangeable

F = the products are *frequently* interchangeable

S = the products are *sometimes* interchangeable

N = the products are *never* interchangeable

0 = *no familiarity* with products from a specified country-pair

Country-pair	China	Other countries
United States		
China	X	
For any country-pair producing calhypo that is <i>sometimes</i> or <i>never</i> interchangeable, please explain the factors that limit or preclude interchangeable use:		

PART IV.--PRICING AND RELATED INFORMATION--Continued

IV-21. **Factors other than price.**--Are differences other than price (*i.e.*, quality, availability, transportation network, product range, technical support, *etc.*) between calhypo produced in the United States and in other countries a significant factor in your firm's sales of the products?

Please indicate A, F, S, N, or 0 in the table below:

A = such differences are *always* significant

F = such differences are *frequently* significant

S = such differences are *sometimes* significant

N = such differences are *never* significant

0 = *no familiarity* with products from a specified country-pair

Country-pair	China	Other countries
United States		
China	X	
<p>For any country-pair for which factors other than price <i>always</i> or <i>frequently</i> are a significant factor in your firm's sales of calhypo, identify the country-pair and report the advantages or disadvantages imparted by such factors:</p>		

PART IV.--PRICING AND RELATED INFORMATION--Continued

IV-22. **Customer Identification**--Please identify the names and contact information for your firm's 10 largest U.S. customers for calhypo since January 1, 2011. Indicate the share of the quantity of your firm's total shipments of calhypo that each of these customers accounted for in 2013.

	Customer's name	City and state	Share of 2013 sales (%)
1		City ' State	
2		City ' State	
3		City ' State	
4		City ' State	
5		City ' State	
6		City ' State	
7		City ' State	
8		City ' State	
9		City ' State	
10		City ' State	

PART IV.--PRICING AND RELATED INFORMATION--Continued

IV-23. Competition From Imports--Lost Revenue.--

Since January 1, 2011: To avoid losing sales to competitors selling calhypso from China, did your firm:

	No	Yes
Reduce prices	<input type="checkbox"/>	<input type="checkbox"/>
Roll back announced price increases	<input type="checkbox"/>	<input type="checkbox"/>

Please DO NOT RE-SUBMIT allegations provided in the preliminary phase of this proceeding.

If you indicated "yes" above, please furnish the following information for each affected transaction. If possible, provide documentation (e.g., copies of invoices, sales reports, or letters from customers). Please note that the Commission may contact the firms named to verify the allegations reported.

- Customer name, contact person, phone and fax numbers
- Specific product(s) involved
- Date of your firm's initial price quotation
- Quantity involved
- Your firm's initial *rejected* price quotation (total delivered value)
- Your firm's *accepted* price quotation (total delivered value)
- The country of origin of the competing imported product
- The competing price quotation of the imported product (total delivered value)

Customer name, contact person, email, phone and fax numbers	Product	Country of origin	Date of quote	Quantity (pounds)	Initial rejected U.S. price (total value-- dollars)	Accepted U.S. price (total value-- dollars)	Competing import price (total value-- dollars)
Firm Contact Email Phone Fax							
Firm Contact Email Phone Fax							
Firm Contact Email Phone Fax							
Firm Contact Email Phone Fax							

PART IV.--PRICING AND RELATED INFORMATION--Continued

IV-24. Competition From Imports--Lost Sales.—

Since January 1, 2011: Did your firm lose sales of calhypo to imports of these products from China?

No **Yes**

Please DO NOT RE-SUBMIT allegations provided in the preliminary phase of this proceeding.

If you indicated “yes” above, please furnish the following information for each affected transaction. If possible, provide documentation (e.g., copies of invoices, sales reports, or letters from customers). Please note that the Commission may contact the firms named to verify the allegations reported.

- Customer name, contact person, phone and fax numbers
- Specific product(s) involved
- Date of your firm’s price quotation
- Quantity involved
- Your firm’s rejected price quotation (total delivered value)
- The country of origin of the competing imported product
- The accepted price quotation of the imported product (total delivered value)

Customer name, contact person, email, phone and fax numbers	Product	Country of origin	Date of quote	Quantity (pounds)	Rejected U.S. price (total value--dollars)	Competing import price (total value—dollars)
Firm Contact Email Phone Fax						
Firm Contact Email Phone Fax						
Firm Contact Email Phone Fax						
Firm Contact Email Phone Fax						

PART IV.--PRICING AND RELATED INFORMATION--Continued

IV-25. **Other explanations.**--If your firm would like to further explain a response to a question in Part IV that did not provide a narrative response box, please note the question number and the explanation in the space provided below. Please also use this space to highlight any issues your firm had in providing the data in this section, including but not limited to technical issues with the MS Word questionnaire.

--